Overview

Attendees of this symposium will gain exposure to emerging clinical and scientific advances in the treatment of chronic lymphocytic leukemia (CLL) with BTK inhibitors (BTKis), including novel pharmacologic targets within the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for BTK inhibitors in both treatment-naive (TN) and relapsed/refractory (R/R) CLL. Attendees will also explore prominent mechanisms of BTK inhibitor resistance and adaptive strategies used to prevent and/or mitigate the development of resistance. Using a case-based approach, discussion focused on common clinical challenges, anticipation and management of adverse events, promotion of patient adherence, and optimization of outcomes for patients with CLL will be integrated into this symposium.

Speakers

Kathy Edwards, PharmD, BCPS, BCOP

Affiliate Associate Professor, College of Pharmacy
Medical University of South Carolina
View Full Bio

Emily Dotson, PharmD, BCOP

Clinical Pharmacist Specialist–Hematology Lead
The James Cancer Hospital
Columbus, Ohio

View Full Bio

Accreditation

CPE

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This -based activity is approved for 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit (UAN JA0007101-000-20-004-L01-P).

Other

Creative Educational Concepts, Inc. certifies this activity for 1.00 hour of participation.

Acknowledgement

This activity is presented by Creative Educational Concepts, Inc. 

This activity is supported through an independent educational grant from AstraZeneca.